 CAMBRIDGE, England, BOSTON-- BUSINESS WIRE --Bicycle Therapeutics plc NASDAQ:BCYC, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide Bicycle technology, today announced that monotherapy dose escalation results of the ongoing Phase III trial of BT8009, a second-generation BTCTM targeting Nectin-4, will be presented at the 2023 American Society for Clinical Oncology ASCO Genitourinary GU Cancers Symposium, being held February 16-18, 2023 in San Francisco, California. On Tuesday, February 14, 2023 at 8:00 a.m. ET, the Company will host a conference call with BT8009 investigator Dr. Capucine Baldini Medical Oncologist, Gustave Roussy and Dr. Daniel Petrylak Professor of Medicine and Genitourinary Oncology, Yale School of Medicine to discuss the data being presented. 